The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Pharmacy Benefits and the Use of Drugs by the Chronically Ill
Abstract
CONTEXT: Many health plans have instituted more cost sharing to discourage use of more expensive pharmaceuticals and to reduce drug spending. OBJECTIVE: To determine how changes in cost sharing affect use of the most commonly used drug classes among the privately insured and the chronically ill. DESIGN, SETTING, AND PARTICIPANTS: Retrospective US study conducted from 1997 to 2000, examining linked pharmacy claims data with health plan benefit designs from 30 employers and 52 health plans. Participants were 528,969 privately insured beneficiaries aged 18 to 64 years and enrolled from 1 to 4 years (960,791 person-years). MAIN OUTCOME MEASURE: Relative change in drug days supplied (per member, per year) when co-payments doubled in a prototypical drug benefit plan. RESULTS: Doubling co-payments was associated with reductions in use of 8 therapeutic classes. The largest decreases occurred for nonsteroidal anti-inflammatory drugs (NSAIDs) (45%) and antihistamines (44%). Reductions in overall days supplied of antihyperlipidemics (34%), antiulcerants (33%), antiasthmatics (32%), antihypertensives (26%), antidepressants (26%), and antidiabetics (25%) were also observed. Among patients diagnosed as having a chronic illness and receiving ongoing care, use was less responsive to co-payment changes. Use of antidepressants by depressed patients declined by 8%; use of antihypertensives by hypertensive patients decreased by 10%. Larger reductions were observed for arthritis patients taking NSAIDs (27%) and allergy patients taking antihistamines (31%). Patients with diabetes reduced their use of antidiabetes drugs by 23%. CONCLUSIONS: The use of medications such as antihistamines and NSAIDs, which are taken intermittently to treat symptoms, was sensitive to co-payment changes. Other medications--antihypertensive, antiasthmatic, antidepressant, antihyperlipidemic, antiulcerant, and antidiabetic agents--also demonstrated significant price responsiveness. The reduction in use of medications for individuals in ongoing care was more modest. Still, significant increases in co-payments raise concern about adverse health consequences because of the large price effects, especially among diabetic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Adverse Events Associated With Prescription Drug Cost-Sharing Among Poor and Elderly Persons
Tamblyn, R. (2001) · JAMA · doi:10.1001/jama.285.4.421 · Cited by 873
Lohr, K. N., Brook, R. H., KAMBERG, C. J., Goldberg, G. A., Leibowitz, A. A., KEESEY, J. W., Reboussin, D. M., & Newhouse, J. P. (1986) · PubMed · Cited by 346
The Effect of Incentive-Based Formularies on Prescription-Drug Utilization and Spending
Huskamp, H. A., Deverka, P. A., Epstein, A. M., Epstein, R. S., McGuigan, K. A., & Frank, R. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmsa030954 · Cited by 334
Risk factor thresholds: their existence under scrutiny
Law, M. R., & Wald, N. J. (2002) · BMJ · doi:10.1136/bmj.324.7353.1570 · Cited by 268
Employer Drug Benefit Plans and Spending on Prescription Drugs
Joyce, G. F. (2002) · JAMA · doi:10.1001/jama.288.14.1733 · Cited by 228
Termination of Medi-Cal Benefits
Lurie, N., Ward, N. B., Shapiro, M. F., Gallego, C., Vaghaiwalla, R., & Brook, R. H. (1986) · New England Journal of Medicine · doi:10.1056/nejm198605083141934 · Cited by 194
Harris, B. L., Stergachis, A., & Ried, L. D. (1990) · Medical Care · doi:10.1097/00005650-199010000-00005 · Cited by 188
Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme Inhibitors
Schneeweiss, S., Walker, A. M., Glynn, R. J., Maclure, M., Dormuth, C., & Soumerai, S. B. (2002) · New England Journal of Medicine · doi:10.1056/nejmsa003087 · Cited by 178
Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization
Motheral, B., & Fairman, K. A. (2001) · Medical Care · doi:10.1097/00005650-200112000-00005 · Cited by 161
The differential impact of copayment on drug use in a Medicaid population.
Reeder, C. E., & Nelson, A. A. (1985) · PubMed · Cited by 111
Johnson, R. E., Goodman, M. J., Hornbrook, M. C., & Eldredge, M. B. (1997) · Europe PMC (PubMed Central) · Cited by 99
Cited by
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729
Goldman, D. P., Joyce, G. F., & Zheng, Y. (2007) · JAMA · doi:10.1001/jama.298.1.61 · Cited by 874
Self-citationHershman, D. L., Kushi, L. H., Shao, T., Buono, D., Kershenbaum, A., Tsai, W.-Y., Fehrenbacher, L., Lin Gomez, S., Miles, S., & Neugut, A. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9655 · Cited by 828
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Dusetzina, S. B., Winn, A. N., Abel, G. A., Huskamp, H. A., & Keating, N. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.9123 · Cited by 500
Cramer, J. A., Benedict, Á., Muszbek, N., Keskinaslan, A., & Khan, Z. M. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01630.x · Cited by 487
Metadata
- Authors
- Goldman, D. P.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2004-05-19
- Volume
- 291
- Issue
- 19
- Pages
- 2344
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1972362505
- Cited by
- 530
- References
- 12
- FWCI
- 114.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.